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INTRODUCTION
Biologic treatments, such as anti-tumour necrosis factor (anti-TNF) therapies, have led to significant improvements in outcomes for patients with inflammatory bowel disease (IBD), but are associated with an increased risk of Mycobacterium tuberculosis (TB) infection [1] . Individual risk of developing M. tuberculosis infection is influenced by the type of biologic drug, concomitant immunosuppressive therapies and other epidemiological factors [2] . Identifying and treating latent TB infection (LTBI) and active TB in the context of biologic therapy is challenging, because the altered immune response gives rise to atypical presentation such as extra-pulmonary and disseminated mycobacterial disease [1] .
The European Crohn's and Colitis Organisation (ECCO) recommend that, before commencing biologic treatment, screening for LTBI should be undertaken using a combination of history, chest X-ray (CXR), and tuberculin skin test (TST) or Interferon Gamma Release Assay (IGRA) according to local prevalence of TB, national guidance and BCG status [3] . TST and IGRA have limitations in diagnosing LTBI, including increased false negatives among immunosuppressed patients [4] .
Although specificity for diagnosing LTBI using IGRAs is reported as 95%, there are issues around reproducibility and indeterminacy of test results [5] . Indeterminate results can occur in 2% of the healthy population [5] , and in up to 12% of immunocompromised or immunosuppressed patients [6] . Whilst it is known that concomitant treatment with steroids can affect IGRA test results, less is known about the effects of other immunosuppressive medications. Indeterminate IGRA results in the context of possible LTBI may delay the initiation of biologic treatment because of the need for repeat testing and consultation with TB services.
The primary aim of this study was to determine rates of LTBI in our IBD cohort treated with biologics by two screening methods -TST (to July 2013) and IGRA (from July 2013). Secondary aims were to determine the effects of different immunosuppressive drugs on the frequency of indeterminate IGRA test results, and to review cases of active TB which developed during biologic treatment.
METHODS
St Mark's Hospital is a national and international referral centre for patients with IBD in North West London, UK. It is part of London North West Healthcare NHS Trust, which serves an ethnically diverse population from the London boroughs of Brent, Harrow and Ealing. Local TB rates are up to 82.9 per 100,000, compared to a London wide average of 13.5 per 100,000 [7] .
We conducted a retrospective case note review of all IBD patients who were screened prior to 
RESULTS
During the study period, 732 patients with IBD who were considered for starting a biological treatment were screened for LTBI with either a TST or IGRA. Of these 732 patients, 485 (66.3%) were screened with a TST of whom 23/485 (4.7%) were positive, and 247 (33.7%) were screened with an IGRA of whom 6/247 (2.4%) were positive (Figure 1) tuberculosis was later isolated from ascitic fluid samples. The patient returned to theatres day 3 post-op for further surgery, which demonstrated a caecal mass with a contained perforation; histology was in keeping with possible CD and further TB cultures were negative.
Three patients had culture confirmed TB, 1 was PCR TB complex positive but culture negative and 2 patients were treated for active TB on the basis of consistent clinical and radiological features. All isolated cultures were fully sensitive to the first line therapies. Two patients presented with miliary TB, 2 had abdominal TB disease, 1 had pleuro-pulmonary TB, and 1 patient presented with both pulmonary and pericardial TB. Treatment duration was for 6 to 12 months depending on the site and severity of disease; 5 patients completed treatment and 1 remained on treatment beyond the study period. 
DISCUSSION
The overall rate of presumed LTBI in this population receiving biologics for IBD was 4%. Time to start biologics after a diagnosis of LTBI at a median of 86 (IQR 56-166) days represents a time lag with potential consequences for patients with IBD. ECCO guidelines suggest delaying anti-TNF treatment for at least 3 weeks after initiating LTBI chemoprophylaxis; this can be shortened if there is clinical urgency for anti-TNF therapy [3] . The timing of starting anti-TNF after initiation of LTBI needs to be individualised according to the risk of developing active TB, the risk of hepatotoxicity with LTBI treatment, severity of underlying IBD disease and patient choice.
The incidence of active TB in this cohort was 1%, which was significantly higher than in the average UK (12.0/100,000) and London (26.2/100,000) general population [8] , but lower than in anti-TNF treated patient cohorts in South Korea (2.9%) [9] and Turkey (4.7%) [10] . Our rate for presumed LTBI (4%) was also lower than in a Korean cohort of anti-TNF treated patients [11] . These differences probably reflect our strategy of active identification of LTBI through screening, and different background TB incidence rates. The high incidence of extra-pulmonary TB in our cohort was consistent with the other studies [12] .
Almost one third of IBD patients in our study had an initial indeterminate IGRA test result, of whom half had a repeat indeterminate result. An indeterminate IGRA result can indicate failure of the positive control, which measures IFN-γ response against phytohaemagglutinin [6] , because of a reduction in the number and function of T lymphocytes or failure of IFN-γ production [13] .
Immunosuppressors, which affect this cell-mediated response, can therefore result in a higher proportion of indeterminate tests. The proportion of indeterminate IGRAs in patients on immunosuppressives was much higher in our study (32%) than in a Swiss IBD cohort (3%), even though a similar proportion of patients in each cohort were on immunosuppressive medication (UK cohort 73%, Swiss cohort 81%) [14] . An explanation for this difference in indeterminate results would require more detailed characterization and comparison of the two cohorts, perhaps including data to characterise IBD activity, which has been shown to be strongly associated with indeterminate IGRAs in paediatric IBD patients [15] .
The high proportion of indeterminate IGRAs in our patient population suggests that risk stratification, including factors such as country of origin and local TB prevalence, may be important in the screening of TB prior to biologic therapy in immunosuppressed patients [16] . However, even with risk stratification some patients may be missed, as demonstrated by the 6 cases in our study who developed active TB, all of whom were deemed to be at low risk of LTBI. This reinforces the message that there is no perfect system to identify all patients with LTBI and that vigilance for active TB in patients on biologics is required.
We included patients with IBD who were screened with TST before the introduction of IGRAs to obtain an overall estimate of the proportion of patients screened who had LTBI. TST can be falsely negative in immunosuppressed patients [17] , therefore we may have underestimated the overall prevalence of LTBI. In practice, patients who come from a high TB prevalence country are considered for LTBI prophylaxis regardless of their TST or IGRA result. Whereas TST or IGRA could be used as LTBI screening in patients from low TB prevalence area without BCG vaccination [18] , early screening with IGRA should be considered in immunosuppressed and BCG vaccinated patients [14] .
Patients on a combination of thiopurines and corticosteroids had the highest proportion of indeterminate IGRA results, although all immunosuppressive medications were associated with a higher rate of indeterminate IGRAs. This has implications for LTBI screening in IBD patients, given the delays associated with indeterminate results. To avoid these delays, LTBI screening could be considered prior to commencement of immunosuppressive medication in IBD patients with severe ulcerative colitis or Crohn's disease, or a patient's baseline risk of LTBI could take precedence over IGRA-based screening. This is similar to the approach recommended in British Thoracic Society guidelines [19] , which were written when TST was the most commonly available LTBI screening test.
Future guidelines need to take into account indeterminate IGRA results, and give weight to epidemiological risk. However, given that all active cases of TB in our study were considered to be of low epidemiological risk, guidance regarding re-screening strategies might also be needed. For example, in treating IBD patients who have been screened and who are receiving prolonged and continuing doses of anti-TNF, close liaison with a TB service is advised [20] , and even negative IGRA test results should not exclude the possibility of LTBI [6] . Any re-screening strategy needs to take into account conversion of TB tests and dynamic IGRA responses during anti TNF-treatment [21] , and
should not exclude patients previously treated with biologics [22] . Taken together, such a strategy has the potential to reduce, if not eliminate, the risk of patients developing active TB. 
FIGURE LEGENDS

